Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
J Ros, C Vaghi, I Baraibar, N Saoudi González… - International Journal of …, 2024 - mdpi.com
Kirsten rat sarcoma virus oncogene homolog (KRAS) is the most frequently mutated
oncogene in human cancer. In colorectal cancer (CRC), KRAS mutations are present in …
oncogene in human cancer. In colorectal cancer (CRC), KRAS mutations are present in …
Targeting KRAS G12C mutations in colorectal cancer
MH Zhao, AW Wu - Gastroenterology Report, 2023 - academic.oup.com
With the advent of Kirsten rat sarcoma viral oncogene homologue G12C (KRAS G12C)
inhibitors, RAS is no longer considered undruggable. For the suppression of RAS, new …
inhibitors, RAS is no longer considered undruggable. For the suppression of RAS, new …
Targeting KRAS oncogene for patients with colorectal cancer: A new step toward precision medicine
KRAS mutations are common driver oncogenes associated with the development of several
solid tumors. KRAS oncogene has been considered a highly challenging target for drug …
solid tumors. KRAS oncogene has been considered a highly challenging target for drug …
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Identifying mutations in the KRAS gene has become increasingly important in the treatment
of colorectal cancer with many prognostic and therapeutic implications. However, efforts to …
of colorectal cancer with many prognostic and therapeutic implications. However, efforts to …
CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
4018 Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) p. G12C mutation is
associated with poor prognosis in colorectal cancer (CRC). AMG 510 is a first-in-class small …
associated with poor prognosis in colorectal cancer (CRC). AMG 510 is a first-in-class small …
Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon …
M Kitazawa, Y Miyagawa… - Molecular and …, 2021 - spandidos-publications.com
Colorectal cancer with a Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) gene
mutation is considered to be resistant to anti‑EGFR agents. G12D is the most common KRAS …
mutation is considered to be resistant to anti‑EGFR agents. G12D is the most common KRAS …
[HTML][HTML] Targeting KRASG12C in colorectal cancer: The beginning of a new era
D Ciardiello, BA Maiorano, E Martinelli - ESMO open, 2023 - Elsevier
Highlights•KRAS G12C mutation occurs in 2%-4% of metastatic colorectal cancer
(mCRC).•The presence of KRAS G12C mutation is correlated with a dismal response to …
(mCRC).•The presence of KRAS G12C mutation is correlated with a dismal response to …
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
BA Caughey, JH Strickler - Drugs, 2024 - Springer
Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated
oncogenes in cancer and the mutational prevalence is especially high in many …
oncogenes in cancer and the mutational prevalence is especially high in many …